Reponex Pharmaceuticals A/S
🇩🇰Denmark
Reponex Pharmaceuticals Prioritizes Clinical Programs for Colon Cancer, Peritonitis, and IBD
Reponex Pharmaceuticals prioritizes RNX-051 for colon adenomas and colon cancer, RNX-011 for peritonitis, and RNX-041 for IBD (pouchitis) due to strong clinical data.
© Copyright 2025. All Rights Reserved by MedPath